VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+2.93%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$182M
AUM Growth
+$182M
(-5.1%)
Cap. Flow
-$9.35M
Cap. Flow
% of AUM
-5.14%
Top 10 Holdings %
Top 10 Hldgs %
6.2%
Holding
508
New
65
Increased
160
Reduced
215
Closed
68
Top Buys
| 1 |
Dow Inc
DOW
|
$1.16M |
| 2 |
Hershey
HSY
|
$1.04M |
| 3 |
Copart
CPRT
|
$1.03M |
| 4 |
lululemon athletica
LULU
|
$1.02M |
| 5 |
Progressive
PGR
|
$999K |
Top Sells
| 1 |
Lennar Class A
LEN
|
$952K |
| 2 |
TJX Companies
TJX
|
$909K |
| 3 |
Ameriprise Financial
AMP
|
$902K |
| 4 |
Abbott
ABT
|
$892K |
| 5 |
Home Depot
HD
|
$885K |
Sector Composition
| 1 | Healthcare | 25.65% |
| 2 | Financials | 14.09% |
| 3 | Technology | 11.21% |
| 4 | Energy | 10.21% |
| 5 | Materials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
CION Investment
CION
$532M
| $217K | 0.12% |
21,969
+7,665
| +54% | +$75.7K |
|
302
Innovative Industrial Properties
IIPR
$1.54B
| $214K | 0.12% |
+2,822
| New | +$214K |
|
303
OFS Capital
OFS
$116M
| $214K | 0.12% |
20,800
+1,915
| +10% | +$19.7K |
|
304
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $212K | 0.12% |
19,696
+351
| +2% | +$3.78K |
|
|
AAT
305
American Assets Trust
AAT
$1.28B
| $207K | 0.11% |
+11,151
| New | +$207K |
|
306
BioNTech
BNTX
$24.1B
| $206K | 0.11% |
1,655
+29
| +2% | +$3.61K |
|
307
Halozyme
HALO
$8.75B
| $201K | 0.11% |
5,262
+92
| +2% | +$3.51K |
|
|
BCIC
308
BCP Investment Corporation Common Stock
BCIC
$160M
| $197K | 0.11% |
9,567
+844
| +10% | +$17.4K |
|
309
Blackstone Secured Lending
BXSL
$6.75B
| $193K | 0.11% |
7,737
+2,708
| +54% | +$67.5K |
|
310
Summit Therapeutics
SMMT
$17.5B
| $192K | 0.11% |
109,761
+66,926
| +156% | +$117K |
|
311
SuRo Capital
SSSS
$207M
| $192K | 0.11% |
52,969
+3,114
| +6% | +$11.3K |
|
312
Rhythm Pharmaceuticals
RYTM
$6.75B
| $186K | 0.1% |
10,404
+183
| +2% | +$3.27K |
|
313
Monroe Capital Corp
MRCC
$164M
| $185K | 0.1% |
24,166
+2,298
| +11% | +$17.6K |
|
314
Oxford Square Capital
OXSQ
$172M
| $180K | 0.1% |
56,821
-9,584
| -14% | -$30.3K |
|
315
Harmony Biosciences
HRMY
$2.16B
| $171K | 0.09% |
5,248
+89
| +2% | +$2.91K |
|
316
TG Therapeutics
TGTX
$5.03B
| $166K | 0.09% |
11,054
-4,254
| -28% | -$64K |
|
317
Lumen
LUMN
$4.84B
| $147K | 0.08% |
+55,532
| New | +$147K |
|
318
Runway Growth Finance
RWAY
$390M
| $147K | 0.08% |
12,121
-2,044
| -14% | -$24.8K |
|
319
Zymeworks
ZYME
$1.07B
| $142K | 0.08% |
15,759
-6,059
| -28% | -$54.8K |
|
320
Pliant Therapeutics
PLRX
$105M
| $140K | 0.08% |
5,279
-2,024
| -28% | -$53.8K |
|
|
MORF
321
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $139K | 0.08% |
3,682
-1,417
| -28% | -$53.3K |
|
322
Scilex Holding
SCLX
$131M
| $137K | 0.08% |
+17,635
| New | +$137K |
|
323
Merus
MRUS
$5.04B
| $134K | 0.07% |
7,305
-2,801
| -28% | -$51.5K |
|
324
Arcturus Therapeutics
ARCT
$467M
| $129K | 0.07% |
5,367
-2,064
| -28% | -$49.5K |
|
325
FibroGen
FGEN
$48.4M
| $125K | 0.07% |
6,711
-2,584
| -28% | -$48.6K |
|